Navigation Links
BioWa Announces License of POTELLIGENT(R) Technology to Merck KGaA
Date:7/15/2009

PRINCETON, N.J., July 15 /PRNewswire/ -- BioWa, Inc. announced today that it has entered into a license agreement with Merck KGaA, Darmstadt, Germany, providing the global healthcare and chemicals company with access to BioWa's POTELLIGENT((R)) Technology platform for the research, development and commercialization of their antibody therapies with enhanced antibody-dependent cellular cytotoxicity (ADCC).

"We are extremely pleased about our partnership with Merck KGaA, a global healthcare company with a strong worldwide presence," commented Dr. Masamichi Koike, BioWa's President and CEO. "Merck KGaA's world-class R&D organization and global market presence will enable us to promote and extend the benefit of the technology to patients all over the world more efficiently."

Under the terms of the license agreement, BioWa grants Merck KGaA non-exclusive rights to research, develop and commercialize therapeutic antibodies generated through POTELLIGENT((R)) Technology for an undisclosed number of targets. In return, BioWa will receive upfront payments, and may receive development milestone payments and royalties on products. Other details of the agreement are not disclosed.

About POTELLIGENT((R)) Technology

POTELLIGENT((R)) Technology improves potency and efficacy of antibody therapeutics, by enhancing ADCC, one of the major mechanisms of action for antibody therapeutics. POTELLIGENT((R)) Technology involves the reduction of the amount of fucose in the carbohydrate structure of an antibody using a proprietary fucosyltransferase-knockout CHO cell line as a production cell. Research shows that POTELLIGENT((R)) Technology dramatically enhances ADCC activity of an antibody in vitro, and significantly increases potency and efficacy of the antibody in vivo. A number of POTELLIGENT((R)) antibodies are being investigated in human clini
'/>"/>

SOURCE BioWa, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. BioWa Announces Licensing of BioWas POTELLIGENT(R) Technology by GlaxoSmithkline for Use in Antibody Research and Development
2. BioWa Announces Expansion of License Agreement with Genentech for BioWas POTELLIGENT(R) Technology
3. Increased Light Leads to Early Detection: Caliper Life Sciences Introduces Bioware(R) Ultra Cancer Cell Lines
4. BioWa and Medarex Announce License of BioWas COMPLEGENT(TM) Technology
5. BioWa Announces License of Biowas Potelligent(R) Technology to KaloBios Pharmaceuticals
6. BioWa Licenses POTELLIGENT(R) Technology to GlaxoSmithKline for Use in Antibody Development and Commercialization
7. BioWa Announces License of POTELLIGENT(R) Technology to sanofi-aventis
8. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
9. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
10. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
11. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... January 22, 2015 Protocol Networks brings ... growing team of brand-neutral, independent consultants, Protocol Networks has ... explained that over the years, his company has attracted ... Town of Plainfield, as well as others. With the ...
(Date:1/22/2015)... Dr. Greg Leyer of UAS Labs recently was invited ... seminar on probiotics in San Diego, CA. , The ... for health care professionals. This year’s pre-conference seminar was held ... health. Dr. Leyer spoke about the emerging topics and science ...
(Date:1/22/2015)... , Nueva Jersey , 22 de enero ... for Biomedical Research abre hoy su llamada a nominaciones ... cuya investigación científica ha hecho, o tiene el potencial ... salud humana. Las nominaciones se aceptarán hasta el 15 ...
(Date:1/22/2015)... N.J. , Jan. 22, 2015  Derma Sciences, ... regeneration company focused on advanced wound care, announces ... placental tissues, have been added to the Premier, ... increases the opportunity for the AMNIOEXCEL® and AMNIOMATRIX® ...
Breaking Biology Technology:Protocol Networks Brings Independent Technology Consulting to the Constitution State 2El Dr. Paul Janssen Award for Biomedical Research emite su llamada a los nominados para 2015 2El Dr. Paul Janssen Award for Biomedical Research emite su llamada a los nominados para 2015 3El Dr. Paul Janssen Award for Biomedical Research emite su llamada a los nominados para 2015 4Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 2Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 3Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 4Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 5
... 4, 2011 Sequenom, Inc. (NASDAQ: SQNM ... solutions, today announced the launch of its iPLEX ADME ... with drug absorption, distribution, metabolism, and excretion (ADME). This ... pre-designed single nucleotide polymorphisms (SNP), insertions and deletions (INDELS) ...
... OXFORD, England, October 4, 2011 PharmaVentures ... of Corporate Finance to significantly enhance Pharmaventures, advisory capabilities ... Fintan Walton, PhD, PharmaVentures, Chief Executive Office ... He brings a wealth of investment management experience and ...
... Calif., October 3, 2011 Glioblastoma is one of ... presenting as a well-defined tumor, glioblastoma will often infiltrate ... treat surgically or with chemotherapy or radiation. Likewise, several ... all treatment attempts. In a new study, a team ...
Cached Biology Technology:Sequenom Introduces iPLEX® ADME PGx Panel on MassARRAY® System 2Sequenom Introduces iPLEX® ADME PGx Panel on MassARRAY® System 3PharmaVentures Appoints Andy Smith as Head of Corporate Finance 2Nanoparticles seek and destroy glioblastoma in mice 2Nanoparticles seek and destroy glioblastoma in mice 3
(Date:12/22/2014)... , Dec. 22, 2014 Research and Markets ... addition of the "The Global Watermarking and ... http://photos.prnewswire.com/prnh/20130307/600769 ... digital media watermarking and fingerprinting markets. Watermarking aims ...
(Date:12/19/2014)... VIEW, Calif. , Dec. 18, 2014  23andMe, Inc., the ... study that pinpoints fine-scale differences in genetic ancestry of individuals ... Since immigrants first arrived more than four hundred years ... as a meeting place for peoples from different continents. This ...
(Date:12/17/2014)...  HITLAB SM announced today its completion of a ... to current U.S. Food and Drug Administration (FDA) regulations. ... and smart phone application trials utilizing the highest principles ... is determined to improve global healthcare access, quality, and ...
Breaking Biology News(10 mins):The Global Watermarking and Fingerprinting Markets 223andMe Study Sketches Genetic Portrait of the United States 223andMe Study Sketches Genetic Portrait of the United States 323andMe Study Sketches Genetic Portrait of the United States 4HITLAB Completes GCP Audit for FDA Smart Device & App Compliance 2
... The first HFSP Nakasone Award has been conferred upon ... on the development of optogenetic methods for studying the ... Award was established to honour scientists who have made ... life sciences. It recognizes the vision of former Prime ...
... longer necessary for growing potatoes, at least for growing ... a research project, together with Neiker-Tecnalia (the Basque Institute ... air, by means of a novel system known as ... experience in Spain, given that never before in this ...
... by the U.S. Food and Drug Administration (FDA) and ... step in advancing efforts toward the development of an ... safe and effective testing of artificial pancreas technology in ... was a strong consensus among leading clinicians, researchers and ...
Cached Biology News:Karl Deisseroth of Stanford University receives HFSP Nakasone Award 2Newco produces seed potatoes in the open air 2Newco produces seed potatoes in the open air 3JDRF clinical panel recommends next steps for artificial pancreas clinical testing 2JDRF clinical panel recommends next steps for artificial pancreas clinical testing 3
... The GeneSwitch Cell Lines stably ... pSwitch. Each cell line is functionally ... transfection with the expression control vector ... expression after treatment with mifepristone (Figure ...
... OrientExpress™ System Modules ... and directional cloning into ... expression vectors ... OrientExpress™ Cloning Systems, the ...
... CHEMICON Re-Blot Western Blot Recycling Kit ... from Western blots that have been ... or other isotopes. It is not ... DAB, 4-chloronapthol, etc.), as it is ...
Applications: Western blotting ...
Biology Products: